Medication Prescriptions for Chronic Diseases in Terminal Cancer Patients in Korea: A Real-World Study.
J Hosp Palliat Care
Department of Family Medicine, Uijeongbu Eulji Medical Center, Eulji University, Uijeongbu, Korea.
Published: March 2025
Purpose: This study aimed to investigate the prescribing patterns of medications for chronic diseases in patients with terminal cancer in South Korea as their life expectancy declined.
Methods: This study analyzed data on cancer patients from the National Health Insurance Service (NHIS) database in South Korea. It included a total of 89,606 patients who died of cancer in 2021. We evaluated prescriptions for dyslipidemia, hypertension, diabetes, and osteoporosis at 52, 12, 4, and 1 week prior to death.
Results: A significant proportion of patients nearing death continued to receive prescriptions for chronic disease medications, despite guidelines suggesting that these medications can be discontinued when life expectancy is limited. For instance, 2.6% of patients were prescribed medications for dyslipidemia just 1 week before death, highlighting a discrepancy between clinical practice and recommended guidelines.
Conclusion: These findings underscore the need to reevaluate prescription practices for terminal cancer patients. Optimizing medication use can decrease polypharmacy, reduce adverse drug reactions, and increase the quality of life (QOL) for these individuals.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC11891024 | PMC |
| http://dx.doi.org/10.14475/jhpc.2025.28.1.18 | DOI Listing |
Similar Publications
Pain and Suffering: The Experience of Patients With Terminal Cancer.
Pain Manag Nurs
March 2025
University Center for Health Sciences, University of Guadalajara, Jalisco, México. Electronic address:
Purpose/objectives: Analyze the meaning of pain and suffering experienced by patients with end-stage cancer from a systemic perspective.
Design: Qualitative study based on General Systems Theory.
Sample/participants: Ten patients with terminal stage cancer were interviewed.
Background: This study aimed to investigate the assignment of" patient attendants"as outlined in the guidelines for home-based red blood cell transfusion therapy in Japan.
Methods: Among patients with cancer who received home-based treatment at our institution during the study period, 93 patients who underwent home-based red blood cell transfusion therapy and either died or were diagnosed in their terminal stage were included. Data were collected from medical records and analyzed retrospectively.
[Current Status and Future Perspectives of Cancer Rehabilitation].
Gan To Kagaku Ryoho
February 2025
Dept. of Rehabilitation Medicine, Keio University School of Medicine.
As cancer becomes more of a chronic condition, cancer rehabilitation care aimed at maintaining and improving patients' quality of life(QOL)is becoming increasingly important. Cancer rehabilitation care addresses both disabilities caused by cancer itself and those that arise during the treatment process. Cancer rehabilitation is divided into four phases-preventive, restorative, supportive, and palliative.
View Article and Find Full Text PDFIsotope-coded hydrazide tags for MALDI-MS based quantitative glycomics.
Talanta
March 2025
The Key Laboratory for Biomedical Photonics of MOE at Wuhan National Laboratory for Optoelectronics, Hubei Bioinformatics & Molecular Imaging Key Laboratory, Systems Biology Theme, Department of Biomedical Engineering, College of Life Science and Technology, Huazhong University of Science and Technology, Wuhan, 430074, China. Electronic address:
The detection of glycosylation alterations is essential for elucidating the roles of glycan functions in biological processes and identifying potential disease biomarkers. Stable isotopic chemical labeling, coupled with mass spectrometry (MS), represents a powerful approach in quantitative glycomics. In this study, we synthesized a novel isotopic hydrazide pair, 2,6-Dimethyl-4-chinolincarbohydrazid (DMQCH) and its deuterium isomer DMQCH-d, via an efficient and cost-effective method, and applied it for the first time in MALDI-MS-based quantitative glycomics.
View Article and Find Full Text PDFcAmbly: A non-toxic cell-penetrating peptide derived from Amblyomin-X with targeted delivery to mitochondrial and cytoplasmic proteins.
PLoS One
March 2025
CENTD, Centre of Excellence in New Target Discovery, Instituto Butantan, São Paulo, Brazil.
The effective delivery of drugs remains a major challenge in the development of new therapeutic molecules. Several strategies have been employed to address this issue, with cell-penetrating peptides (CPPs) standing out due to their ability to traverse cell membranes with minimal cytotoxicity and their relatively straightforward synthesis when conjugated with other molecules. However, while CPPs can successfully enter the cytoplasm, they often lack specificity for particular organelles, leaving target engagement to the drug itself.
View Article and Find Full Text PDFWant AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!
© LitMetric 2025. All rights reserved.